hematological malignancies
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Lymphoma or multiple myeloma patients with indications for autologous hematopoietic stem cell transplantation; 2.ECOG score of 0~2; 3.Age between 18 and 75; 4.More than 3 months of expected survival time; 5.Ability to sign informed consent.
Exclusion criteria
Exclusion criteria: 1.Having severe cardiac, hepatic or renal insufficiency: Serum direct bilirubin, alanine aminotransferase, and aspartate aminotransferase are 2 times higher than the upper limit of normal threshold; an endogenous creatinine clearance of <=50% in serum; cardiac function class II or above or severe arrhythmia; 2.Having history of hematopoietic stem cell mobilization (regardless of protocol); 3.Active infection; 4.Pregnant or lactating woman; 5.Any serious medical condition that would put the patient at an unacceptable risk in participating in this study, or that would require continued active treatment, such as unstable heart disease, stroke, rheumatoid arthritis, lupus, etc.; 6.Received live or live attenuated vaccines within four weeks before enrollment; 7.Patients who cannot receive follow-up treatment in the designated unit of this program, who cannot understand and comply with the research protocol or who cannot sign the informed consent form; 8.Allergy to VP-16, Ara-C and PEG-rhG-CSF.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| when EAP regimen help patients to reach target proportion of collection values; | — |
Secondary
| Measure | Time frame |
|---|---|
| EAP mobilization regimen reaches ideal proportion of collection value;average number of collection;frequency of FN rate; proportion of patients with red cell infusion with ECP regimen;proportion of patients with red cell infusion with EAP regimen;proportion of patients with platelets infusion with EAP regimen.; | — |
Countries
China